Iksuda Therapeutics

Iksuda Therapeutics is a clinical-stage biotech specializing in next-generation antibody-drug conjugates (ADCs) with a mission to design the optimal ADC for specific cancer targets rather than being technology-led. The company has built a pipeline featuring both clinical-stage assets targeting known antigens like CD19 and HER2, and a next-wave pipeline utilizing its proprietary ProAlk payload platform. With a world-class R&D team and a flexible technology model, Iksuda aims to become a partner of choice in the ADC space while advancing therapies for cancers with high unmet need.

Integrated ADC design platform featuring a novel protein alkylating payload class ('ProAlk'), tumor-selective payload activation linkers, advanced bioconjugation for controlled drug loading, and sophisticated binder engineering (biparatopic, bispecific, Fc-variants).

Iksuda competes in the highly competitive ADC field against large pharma (e.g., AstraZeneca, Pfizer, Gilead) and numerous biotechs. Its differentiation relies on a bespoke, non-dogmatic design approach and the novel ProAlk payload, rather than a single dominant platform technology.